FIELD: medicine; biology.
SUBSTANCE: invention relates to medicine and biology and is intended for the prevention and treatment of coronavirus infections by using phthalhydrazide derivatives including Tamerite, which have immunomodulatory activity alone or in combination with antiviral drugs of various chemical structures. A method for the prevention of coronavirus infection is presented. To increase the clinical and laboratory efficiency achieved by antiviral agents of the azoloazine series (Triazavirin®, Maktavirin®), antimalarial agents and interferon preparations, a drug based on the salt of aminophthalhydrazide derivatives is used in combination with these drugs in the form of a dihydrate, monohydrate, anhydrate in any crystalline form including Tamerite at a dose of 0.01 to 4000 mg/kg by an individual in need thereof.
EFFECT: such drug use (according to the results of preclinical studies) showed that Tamerite provides an overall level of protection up to 100%, which exceeds the level of protection against the use of antiviral drugs alone by 30-50% and reduces the duration of the acute period of the disease by 1.5-2 weeks generally.
5 cl, 3 dwg, 8 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
VACCINE AND METHOD FOR INCREASING IMMUNOGENICITY AND SPECIFIC ACTIVITY OF INFECTION PREVENTION AGENTS | 2020 |
|
RU2741834C1 |
MEDICINAL AGENT | 2000 |
|
RU2163122C1 |
DERIVATIVES OF DI(DIAZONIADISPIRO[5.2.5.2]HEXADECANE)-5-NITROPYRIMIDINE AND THEIR USE FOR TREATMENT OF CORONAVIRUS INFECTIONS, IN PARTICULAR CAUSED BY SARS-COV-2 VIRUS | 2020 |
|
RU2761950C1 |
MEFLOQUINE AND COMBINATIONS THEREOF FOR TREATING AND PREVENTING A CORONAVIRUS INFECTION | 2020 |
|
RU2763024C1 |
MODIFIED ANTISENSE OLIGONUCLEOTIDE AGAINST SARS-CoV-2 | 2020 |
|
RU2750584C1 |
MEDICINAL PREPARATION AND METHOD OF ITS PREPARING | 2001 |
|
RU2193883C1 |
Respiratory therapy method for new coronavirus infection COVID-19 in patients on artificial lung ventilation | 2020 |
|
RU2744550C1 |
INDOLE-3-CARBOXYLIC ACID DERIVATIVE HAVING ANTIVIRAL ACTIVITY ON SARS-CoV-2 | 2022 |
|
RU2820633C1 |
2-(IMIDAZOL-4-YL)-ETHANAMIDE OF PENTANEDIOIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING COVID-19 AND SYMPTOMS THEREOF | 2021 |
|
RU2824607C2 |
METHOD FOR CORONAVIRUS INFECTION TREATMENT | 2021 |
|
RU2751488C1 |
Authors
Dates
2021-05-05—Published
2020-07-17—Filed